The Double-Edged Sword of Epidermal Growth Factor Receptor Inhibitor: Rash as Toxicity and Prognostic Marker
June 2026
in “
Indian Journal of Postgraduate Dermatology
”
Studysummary In this reported case, a 50-year-old man developed an acneiform rash, a common skin side effect of EGFR inhibitor therapy, after starting lapatinib for breast cancer; treatment with doxycycline and hydrocortisone cream led to significant improvement within one week.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on ijpgderma.org →